Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients (NCT05626530)
A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
🩺 Plain-English Summary (8th-Grade Level)
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Who can join: Review the eligibility criteria below.
Location: Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases — Boston, Massachusetts
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 636-5244
Email: Jennifer.Chow@TuftsMedicine.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cytomegalovirus Infections
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation — Phoenix, Arizona
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Houston, Texas
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients — Philadelphia, Pennsylvania
- T Cell Therapy of Opportunistic Cytomegalovirus Infection — Cleveland, Ohio
Explore by condition: All Cytomegalovirus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.